Special Issue

Metabolomics and Chronic Obstructive Lung Diseases

Message from the Guest Editor

The generation of metabolomic data in large epidemiological cohorts is now a reality, enabling the use of metabolomics to study the pathogenesis of many high impact diseases. Chronic obstructive lung diseases (COLDs) represent a group of common respiratory illnesses. COLDs are complex in nature, with influences from both genetics and the environment. While genetic variants have been identified for several COLDs, much remains to be understood about the ways in which these variants impact disease. Metabolomics represents an area of research that has the potential to contribute substantially to the understanding of disease etiology. This Special Issue highlights the use of metabolomics in COLDs. Specific areas include, but are not limited to, using metabolomics to study the etiology of COLDs; the generation of metabolic biomarkers for COLDs: the integration of multi-omic data for COLDs. bioinformatics, statistical, network, and analytic approaches that are relevant for COLDs, study design for the metabolomics of COLDs, and tissue-specific metabolomics for respiratory disease., Sc.D.


Guest Editor

Dr. Jessica Lasky-Su

Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

closed (31 January 2020)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/20527

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

